Quanta Therapeutics Inc. has announced progression of its pipeline of KRAS-directed drug candidates, with the receipt of IND approval from the FDA for QTX-3034.
Bispecific antibodies acting through CEACAM5/CD3 targeting have limited efficacy due to dose-limiting toxicities, insufficient T-cell activation and formation of anti-drug antibodies (ADAs). Researchers from Novimmune SA and Lampkap Bio Alpha AG have published data on a CEACM5/CD3 bispecific antibody, NILK-2301, which is formed by a heavy chain plus two different light chains (kappa and lambda body) as a potential immunotherapeutic with better efficacy and lower potential for ADA formation.
Starpharma Holdings Ltd.’s DEP docetaxel phase II trial met its primary endpoints, demonstrating antitumor activity in multiple advanced, metastatic cancers, including pancreatic, gastro-esophageal, non-small-cell lung cancer and cholangiocarcinoma.
The contribution of alternative RNA splicing in the progression of pancreatic ductal adenocarcinoma (PDAC) has not been deeply explored. In a recent study, the RNA-binding protein RNA binding fox-1 homolog 2 (RBFOX2) was investigated, since its role in modulating alternative splicing in PDAC is not well understood.
Starpharma Holdings Ltd.’s DEP docetaxel phase II trial met its primary endpoints, demonstrating antitumor activity in multiple advanced, metastatic cancers, including pancreatic, gastro-esophageal, non-small-cell lung cancer and cholangiocarcinoma.
Phenomic AI Inc. has announced new collaboration agreements to help advance drug discovery for stroma-rich tumors using its Sctx single-cell transcriptomics platform.
Cancer Research Technology Ltd. has described inhibitors of nuclear factor κB kinase subunit α (CHUK; IKK-1; IKK-α) reported to be useful for the treatment of inflammation and cancer.
Why cancer? The mechanisms that drive and maintain tumorigenesis are still a mystery. This is a play with different actors who have different roles in several contexts. One of these scenarios is represented by genetic and epigenetic conditions that determine the early trajectories of cancer cells. In addition, different mechanisms will control phenotypes and states that can take one or another direction toward cancer.
Medshine Discovery Inc. has disclosed fused quinazoline compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of solid tumors.
